ClinicalTrials.gg
TerminatedNCT04179864CELLO-1Updated Mar 10, 2026Results posted

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

A Phase 1/2 interventional study of Tazemetostat and Abiraterone/prednisone in Metastatic Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Epizyme, Inc.. Terminated at 24 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
40th of 125
102 · median 52
Started
2019
with 6 others
Phase 1/2
11 of 125
5 open now
Registered
98th of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 40th largest by enrollment, is one of 7 that started in 2019, is one of 11 in phase 1/2, and was the 98th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC.

This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.

03

Conditions studied

  • Metastatic Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • metastatic castration resistant prostate cancer
  • tazemetostat
  • EPZ-6438
  • E7438
  • enzalutamide
  • abiraterone
  • Prednisone
  • Zytiga
  • Xtandi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at the time of consent ≥ 18 years.
  2. (ECOG) performance status 0 to 1 (Appendix
  3. of > 3 months.
  4. or cytologically confirmed adenocarcinoma of the prostate. Small cell or neuroendocrine tumors of the prostate are also permitted.
  5. Progressive disease in the setting of medical or surgical castration (ie, castration- resistant prostate cancer [CRPC]) by PCWG3 criteria for study entry.

    • Evidence of disease progression by rising PSA or
    • Soft tissue progression per 1.1 or
    • Evidence of disease progression by observation of 2 new bone lesions since the initiation of last systemic therapy.
  6. prostate cancer disease, documented by the following imaging

    • Bone lesions on bone scan (per PCWG3) or by soft tissue disease (per RECIST 1.1) by CT/MRI imaging Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist.
  7. Prior treatment with a second-generation androgen inhibitor as follows:

    • For phase 1b, EITHER Previously untreated with or progressed on a second generation androgen inhibitor (abiraterone, enzalutamide, or apalutamide) OR progressed on a second generation inhibitor (inhibitor (abiraterone, enzalutamide, or apalutamide)
    • For phase 2 randomized component (i.e, enzalutamide- containing treatment arms) of the study, previously progressed on abiraterone.

Exclusion criteria

Exclusion Criteria:

  1. Known symptomatic
  2. Treatment with any of the following for prostate cancer within the indicated timeframe prior to day 1 of starting study treatment:

    • First generation: AR antagonists (eg, bicalutamide, nilutamide, flutamide) within 4 weeks.
    • 5-alpha-reductase inhibitors, ketoconazole, estrogens (including diethylstilbesterol), or progesterones within 2 weeks.
    • Chemotherapy (except as permitted in inclusion criteria #10) within 3 weeks.
    • Prior radionuclide therapy within 4 weeks.
    • Another interventional product or standard agent in a clinical study within 28 days prior to the first planned dose of Tazemetostat
    • For phase 2 subjects to be randomized to one of the enzalutamide treatment arms only, prior treatment with the second-generation androgen antagonist including enzalutamide, apalutamide, darolutamide, and proxalutamide, etc.
  3. Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for enrollment
  4. Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone

    In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity

    Drug: Tazemetostat · Drug: Abiraterone/prednisone

  • Experimental
    Phase 1b: Tazemetostat in Combination with Enzalutamide

    In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity

    Drug: Tazemetostat · Drug: Enzalutamide

  • Experimental
    Phase 2: Tazemetostat in Combination with Enzalutamide

    Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone. All participants will receive treatment in 28-day cycles.

    Drug: Tazemetostat · Drug: Enzalutamide

  • Active comparator
    Phase 2: Enzalutamide only

    In Phase 2, Enzalutamide will be administered on cycle 1 day 1

    Drug: Enzalutamide

Interventions

  • Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene

    Also known as: EPZ-6438, E7438, IPN60200

  • DrugAbiraterone/prednisone

    1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.

    Also known as: Zytiga

  • enzalutamide 160 mg (four 40 mg capsules) orally once daily

    Also known as: Xtandi

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after the end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.

    Time frame: From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks

  2. Phase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat

    RP2D was based on pharmacokinetics (PK) parameters, pharmacodynamics (PD) parameters as well as efficacy and the overall tolerability of each combination (tazemetost with enzalutamide or tazemetostat with abiraterone/prednisone).

    Time frame: From Day 1 up to Day 28 of Cycle 1 (each cycle was 28 days)

  3. Phase 2: Radiographic Progression-Free Survival (rPFS)

    rPFS was defined as the time from date of randomization (phase 2)/date of first dose of study drug (phase 1b) to the first objective evidence of radiographic progression using response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) (soft tissue) and prostate cancer clinical trials working group 3 (PCWG3) (bone), or death from any cause, whichever occurred first. The radiographic PD for soft tissue lesion was determined based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria and no confirmatory scan was required for soft tissue PD; for bone lesion was determined by 2 or more new bone lesions on bone scan per PCWG3 criteria (i.e., the appearance of 2 or more new bone lesions on bone scan) and the 2 scans (i.e., the confirmatory scan is required for bone disease progression) should be at least 6 weeks apart from each other.

    Time frame: Assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study. Approximately 200 weeks

Secondary outcomes

  1. Phase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response

    Blood samples were collected for evaluation of PSA. Confirmed PSA50 response was defined as \>=50% decline of PSA from baseline at any time on study for participants with a baseline PSA \>=1.0 microgram per liter (mcg/L) (nanogram/milliliter \[ng/mL\]) per PCWG3 criteria. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

    Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively

  2. Phase 1b and 2: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions, any pathological lymph nodes (LN) must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks

  3. Phase 1b and 2: Best Overall Response (BOR)

    BOR was defined as percentage of participants with CR, PR, stable disease (SD), PD, or not evaluable (NE). CR was defined as disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the drug started. In addition, the sum had an absolute increase from nadir of 5 mm. NE was defined as which cannot be classified by 1 of the above preceding definitions. Percentages are rounded off to the tenth decimal place.

    Time frame: Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks

  4. Phase 1b and 2: Disease Control Rate (DCR) at 6 Months

    DCR at 6 months (24 weeks) was defined as percentage of participants with measurable soft tissue disease at baseline who had BOR of CR or PR and remaining on study without progression at 23 weeks or with a duration of SD for at least 23 weeks after of randomization (phase 2)/first dose (phase 1b) using overall imaging-based response assessed by RECIST 1.1 (soft tissue) and PCWG-3 criteria (bone). BOR: percentage of participants with CR, PR, SD, PD, or NE. CR: disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR: at least a 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: at least a 20% increase in sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the drug started. In addition, sum had an absolute increase from nadir of 5 mm.

    Time frame: Baseline and at 6 months (24 weeks)

  5. Phase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria

    Time to first SRE per PCWG3 criteria was defined as the time from the date of randomization (phase II)/date of the first dose of study drug (phase Ib) to the date of first SRE. An SRE was defined as radiation therapy or surgery to bone, pathologic bone fracture, or spinal cord compression.

    Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks

  6. Phase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer

    TTNT was defined as the time from the date of randomization (phase II)/date of the first dose of the study drug (phase Ib) to the date of the first documented administration of systemic treatment for prostate cancer.

    Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks

  7. Phase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP)

    TTPP was defined as the duration from the date of randomization (phase II)/date of first dose of study drug (phase Ib) to the date of first PSA progression per PCWG3 criteria. PSA progression was defined as a \>=25% increase and an absolute increase of \>=2 mcg/L (2 ng/mL) above the nadir (or baseline value for participants who did not have a decline in PSA value beyond 12 weeks). Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

    Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks

  8. Phase 1b and 2: Percentage of Participants With Reduction in Circulating Tumor Cells (CTC)

    Blood samples were collected for evaluation of CTC. Reduction in CTC was defined as participants from a state of having a detectable number of CTCs to having an undetectable number of CTCs. Percentage of participants with detectable CTC at baseline and non-detectable CTC are presented. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization. Percentage of participants with detectable CTC at baseline and non-detectable CTC at any post-baseline time point up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively are presented.

    Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively

  9. Phase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response

    Blood samples were collected for evaluation of CTC. CTC response was defined as a \>=30% reduction in CTC number from baseline in participants who entered the study. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

    Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively

  10. Phase 2: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of the study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.

    Time frame: From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 191 weeks

  11. Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Tazemetostat

    Blood samples were collected at specified timepoints for the assessment of AUC0-last of tazemetostat.

    Time frame: Cycle 1 Days 2 and 21 (each cycle was 28 days)

  12. Phase 1b: Maximum Plasma Concentration (Cmax) of Tazemetostat

    Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat.

    Time frame: Cycle 1 Days 2 and 21 (each cycle was 28 days)

  13. Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 8 Hours Post-Dose (AUC0-8) of Tazemetostat

    Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat.

    Time frame: Up to 8 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)

  14. Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 12 Hours Post-Dose (AUC0-12) of Tazemetostat

    Blood samples were collected at specified timepoints for the assessment of AUC0-12 of tazemetostat.

    Time frame: Up to 12 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)

  15. Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose (AUC0-24) of Enzalutamide

    Blood samples were collected at specified timepoints for the assessment of AUC0-24 of enzalutamide.

    Time frame: Up to 24 hours post-dose on Cycle 1 Days 1, 2 and 21 (each cycle was 28 days)

  16. Phase 2: Maximum Plasma Concentration of Enzalutamide

    For Phase 2, PK blood samples for assessment of Cmax of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

    Time frame: Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)

  17. Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Enzalutamide

    For Phase 2, PK blood samples for assessment of AUC0-last of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

    Time frame: Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)

  18. Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose of Enzalutamide

    For Phase 2, PK blood samples for assessment of enzalutamide AUC0-24 were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

    Time frame: Up to 24 hours post-dose on Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and up to 24 hours post-dose on Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)

  19. Phase 2: Change From Baseline in Functional Assessment of Cancer Therapy-Prostrate (FACT-P): Functional Well-being Subscale (FWB) and Prostate Cancer Subscale (PCS) Scores

    FACT-P questionnaire included subscales:physical well-being(PWB) (Questions \[Q\] GP1 to GP7),social/family well-being subscale(SWB) (Q GS1 to GS7),emotional well-being subscale(EWB) (Q GE1 to GE6),functional well-being subscale(FWB) (Q GF1 to GF7) and prostate cancer subscale(PCS) (Q C2, C6, P1 to P8, BL2 and BL5). Each question had 5 responses, 0: "not at all", 1: "a little bit", 2: "somewhat", 3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Q that were reversed (via subtraction of the response from 4) were: GP1-7, GE1, GE3-6, C2, P1-3, P6-P8 and BL2. Total FACT-P score was sum of scores of all sub-scales (PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. Baseline: last value recorded for a variable prior to or on date of randomization. Change from baseline in FWB and PCS scores is presented.

    Time frame: Baseline (Day 1), Cycle (C) 3 Day 57, C 5 Day 113, C 7 Day 169, C 10 Day 253, C 13 Day 337, C 14 Day 421, C 15 Day 505, C 16 Day 589, C 17 Day 673, C 18 Day 757, C 19 Day 841, C 20 Day 925, C 21 Day 1009, C 22 Day 1093, C 23 Day 1177 and C 24 Day 1261

  20. Phase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score

    TTD was defined as the interval from date of randomization until date of first clinically meaningful deterioration (3 points or more decline for subscale score, 10 points or more decline for total score) that was confirmed at subsequent visit at least 3 weeks apart with no improvement in between visits or death (by any cause) in absence of a clinically meaningful deterioration, regardless of whether participant discontinued study drug(s) prior to deterioration. PCS included Q C2, C6, P1 to P8, BL2 and BL5. Each question had 5 responses,0: "not at all",1: "a little bit",2: "somewhat",3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Total FACT-P: sum of scores of all sub-scales(PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. TDD in prostate symptoms as assessed by FACT-P: PCS score is presented.

    Time frame: Baseline (Day 1) up to Cycle 24 Day 1261

07

Results

Posted Mar 10, 2026
Limitations and caveats
The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in mCRPC and the primary endpoint was not met for this study. There were no safety concerns.

Participant flow

This Phase 1b/2, 2-part, open-label study was conducted at 21 sites in asymptomatic or mildly symptomatic participants with progressive, metastatic castration resistant prostate cancer (mCRPC).

Participant flow — Overall Study
MilestonePhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Started233331334140
Completed0000000000
Not completed233331334140
Withdrew: Progressive disease133321332828
Withdrew: Adverse event1000000031
Withdrew: Sponsor request0000100000
Withdrew: Withdrawal by subject0000000055
Withdrew: Study terminated by sponsor0000000032
Withdrew: Physician decision0000000012
Withdrew: Death0000000002
Withdrew: Non- compliance with study drug0000000010

Outcome measures

PrimaryPhase 1b: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after the end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.

Time frame:
From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone
Treatment-emergent non-serious AEs23333133
TESAEs01002011
PrimaryPhase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat

RP2D was based on pharmacokinetics (PK) parameters, pharmacodynamics (PD) parameters as well as efficacy and the overall tolerability of each combination (tazemetost with enzalutamide or tazemetostat with abiraterone/prednisone).

Time frame:
From Day 1 up to Day 28 of Cycle 1 (each cycle was 28 days)
Reported as:
Number · mg
Phase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat
mgPhase 1b: Tazemetostat Dose-escalation
Phase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat1200
PrimaryPhase 2: Radiographic Progression-Free Survival (rPFS)

rPFS was defined as the time from date of randomization (phase 2)/date of first dose of study drug (phase 1b) to the first objective evidence of radiographic progression using response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) (soft tissue) and prostate cancer clinical trials working group 3 (PCWG3) (bone), or death from any cause, whichever occurred first. The radiographic PD for soft tissue lesion was determined based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria and no confirmatory scan was required for soft tissue PD; for bone lesion was determined by 2 or more new bone lesions on bone scan per PCWG3 criteria (i.e., the appearance of 2 or more new bone lesions on bone scan) and the 2 scans (i.e., the confirmatory scan is required for bone disease progression) should be at least 6 weeks apart from each other.

Time frame:
Assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study. Approximately 200 weeks
Reported as:
Median · months
Phase 2: Radiographic Progression-Free Survival (rPFS)
monthsPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 2: Radiographic Progression-Free Survival (rPFS)22.1 (16.6 to 27.6)11.1 (5.7 to 16.5)
SecondaryPhase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response

Blood samples were collected for evaluation of PSA. Confirmed PSA50 response was defined as \>=50% decline of PSA from baseline at any time on study for participants with a baseline PSA \>=1.0 microgram per liter (mcg/L) (nanogram/milliliter \[ng/mL\]) per PCWG3 criteria. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

Time frame:
From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Reported as:
Number · percentage of participants
Phase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response28.6 (8.39 to 58.10)14.3 (0.36 to 57.87)19.5 (8.82 to 34.87)15.0 (5.71 to 29.84)
SecondaryPhase 1b and 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions, any pathological lymph nodes (LN) must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks
Reported as:
Number · percentage of participants
Phase 1b and 2: Objective Response Rate (ORR)
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Objective Response Rate (ORR)16.7 (0.42 to 64.12)0.0 (0 to 97.50)10.0 (0.25 to 44.50)0.0 (0 to 23.16)
SecondaryPhase 1b and 2: Best Overall Response (BOR)

BOR was defined as percentage of participants with CR, PR, stable disease (SD), PD, or not evaluable (NE). CR was defined as disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the drug started. In addition, the sum had an absolute increase from nadir of 5 mm. NE was defined as which cannot be classified by 1 of the above preceding definitions. Percentages are rounded off to the tenth decimal place.

Time frame:
Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks
Reported as:
Number · percentage of participants
Phase 1b and 2: Best Overall Response (BOR)
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Complete response0.00.00.00.0
Partial response16.70.010.00.0
Stable disease66.7100.070.057.1
Progressive disease16.70.020.035.7
Not evaluable0.00.00.07.1
SecondaryPhase 1b and 2: Disease Control Rate (DCR) at 6 Months

DCR at 6 months (24 weeks) was defined as percentage of participants with measurable soft tissue disease at baseline who had BOR of CR or PR and remaining on study without progression at 23 weeks or with a duration of SD for at least 23 weeks after of randomization (phase 2)/first dose (phase 1b) using overall imaging-based response assessed by RECIST 1.1 (soft tissue) and PCWG-3 criteria (bone). BOR: percentage of participants with CR, PR, SD, PD, or NE. CR: disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR: at least a 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: at least a 20% increase in sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the drug started. In addition, sum had an absolute increase from nadir of 5 mm.

Time frame:
Baseline and at 6 months (24 weeks)
Reported as:
Number · percentage of participants
Phase 1b and 2: Disease Control Rate (DCR) at 6 Months
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Disease Control Rate (DCR) at 6 Months50.0 (11.81 to 88.19)100.0 (2.50 to 100)40.0 (12.16 to 73.76)21.4 (4.66 to 50.80)
SecondaryPhase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria

Time to first SRE per PCWG3 criteria was defined as the time from the date of randomization (phase II)/date of the first dose of study drug (phase Ib) to the date of first SRE. An SRE was defined as radiation therapy or surgery to bone, pathologic bone fracture, or spinal cord compression.

Time frame:
From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Reported as:
Median · months
Phase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria
monthsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria16.2 (4.4 to NA)26.3 (4.0 to NA)NA (16.9 to NA)NA (9.0 to NA)
SecondaryPhase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer

TTNT was defined as the time from the date of randomization (phase II)/date of the first dose of the study drug (phase Ib) to the date of the first documented administration of systemic treatment for prostate cancer.

Time frame:
From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Reported as:
Median · months
Phase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer
monthsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer8.2 (2.6 to 13.9)13.4 (5.4 to NA)9.0 (6.5 to 17.0)10.6 (5.0 to 15.9)
SecondaryPhase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP)

TTPP was defined as the duration from the date of randomization (phase II)/date of first dose of study drug (phase Ib) to the date of first PSA progression per PCWG3 criteria. PSA progression was defined as a \>=25% increase and an absolute increase of \>=2 mcg/L (2 ng/mL) above the nadir (or baseline value for participants who did not have a decline in PSA value beyond 12 weeks). Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

Time frame:
From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Reported as:
Median · months
Phase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP)
monthsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP)4.6 (2.1 to 8.3)2.8 (2.8 to 4.6)4.6 (3.3 to 11.1)3.0 (2.8 to 5.6)
SecondaryPhase 1b and 2: Percentage of Participants With Reduction in Circulating Tumor Cells (CTC)

Blood samples were collected for evaluation of CTC. Reduction in CTC was defined as participants from a state of having a detectable number of CTCs to having an undetectable number of CTCs. Percentage of participants with detectable CTC at baseline and non-detectable CTC are presented. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization. Percentage of participants with detectable CTC at baseline and non-detectable CTC at any post-baseline time point up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively are presented.

Time frame:
From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Reported as:
Number · percentage of participants
Phase 1b and 2: Percentage of Participants With Reduction in Circulating Tumor Cells (CTC)
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Detectable CTC at baseline64.3100.036.652.5
Non-detectable CTC35.70.063.447.5
SecondaryPhase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response

Blood samples were collected for evaluation of CTC. CTC response was defined as a \>=30% reduction in CTC number from baseline in participants who entered the study. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.

Time frame:
From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Reported as:
Number · percentage of participants
Phase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response
percentage of participantsPhase 1b: Tazemetostat + EnzalutamidePhase 1b: Tazemetostat + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response88.9 (51.75 to 99.72)100.0 (59.04 to 100.00)80.0 (51.91 to 95.67)42.9 (21.82 to 65.98)
SecondaryPhase 2: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of the study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.

Time frame:
From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 191 weeks
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events
ParticipantsPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Treatment-emergent non-serious AEs4139
TESAEs1310
SecondaryPhase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Tazemetostat

Blood samples were collected at specified timepoints for the assessment of AUC0-last of tazemetostat.

Time frame:
Cycle 1 Days 2 and 21 (each cycle was 28 days)
Reported as:
Mean · hour*nanograms per milliliter (ng/mL)
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Tazemetostat
hour*nanograms per milliliter (ng/mL)Phase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone
Cycle 1 Day 21640 ± 1503350 ± 20202860 ± 8667060 ± 15806830 ± 5880NA ± NA3480 ± 29904380 ± 4680
Cycle 1 Day 21NA ± NA1230 ± 1681490 ± 6062800 ± 20201120 ± 620NA ± NA2290 ± 11003500 ± 1570
SecondaryPhase 1b: Maximum Plasma Concentration (Cmax) of Tazemetostat

Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat.

Time frame:
Cycle 1 Days 2 and 21 (each cycle was 28 days)
Reported as:
Mean · ng/mL
Phase 1b: Maximum Plasma Concentration (Cmax) of Tazemetostat
ng/mLPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone
Cycle 1 Day 2341 ± 69.3911 ± 609888 ± 97.81470 ± 2171730 ± 1100NA ± NA851 ± 3481060 ± 916
Cycle 1 Day 21NA ± NA364 ± 36.8530 ± 436568 ± 341254 ± 118NA ± NA810 ± 3271140 ± 646
SecondaryPhase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 8 Hours Post-Dose (AUC0-8) of Tazemetostat

Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat.

Time frame:
Up to 8 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)
Reported as:
Mean · hour*ng/mL
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 8 Hours Post-Dose (AUC0-8) of Tazemetostat
hour*ng/mLPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone
Cycle 1 Day 21240 ± 7053350 ± 20202860 ± 8667060 ± 15806830 ± 5880NA ± NA3130 ± 23904380 ± 4680
Cycle 1 Day 21NA ± NA1230 ± 1681490 ± 6063770 ± 15901440 ± 310NA ± NA2280 ± 15603500 ± 1570
SecondaryPhase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 12 Hours Post-Dose (AUC0-12) of Tazemetostat

Blood samples were collected at specified timepoints for the assessment of AUC0-12 of tazemetostat.

Time frame:
Up to 12 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)
Reported as:
Mean · hour*ng/mL
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 12 Hours Post-Dose (AUC0-12) of Tazemetostat
hour*ng/mLPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone
Cycle 1 Day 2NA ± NA—NA ± NANA ± NANA ± NANA ± NA4480 ± 3460NA ± NA
Cycle 1 Day 21—1300 ± 1211800 ± 863——NA ± NANA ± NA—
SecondaryPhase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose (AUC0-24) of Enzalutamide

Blood samples were collected at specified timepoints for the assessment of AUC0-24 of enzalutamide.

Time frame:
Up to 24 hours post-dose on Cycle 1 Days 1, 2 and 21 (each cycle was 28 days)
Reported as:
Mean · hour*ng/mL
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose (AUC0-24) of Enzalutamide
hour*ng/mLPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + Enzalutamide
Cycle 1 Day 1NA ± NA33000 ± 1560028800 ± 578036800 ± 644027500 ± 5270
Cycle 1 Day 256700 ± 790057700 ± 3010057400 ± 1840066800 ± 1050060300 ± 19900
Cycle 1 Day 21NA ± NA272000 ± 106000263000 ± 50400251000 ± 47400199000 ± 30800
SecondaryPhase 2: Maximum Plasma Concentration of Enzalutamide

For Phase 2, PK blood samples for assessment of Cmax of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

Time frame:
Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Reported as:
Mean · ng/mL
Phase 2: Maximum Plasma Concentration of Enzalutamide
ng/mLPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Cycle 1 Day 1—3000 ± 577
Cycle 1 Day 23960 ± 773—
Cycle 1 Day 2112100 ± 3080—
SecondaryPhase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Enzalutamide

For Phase 2, PK blood samples for assessment of AUC0-last of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

Time frame:
Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Reported as:
Mean · hour*ng/mL
Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Enzalutamide
hour*ng/mLPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Cycle 1 Day 1—30100 ± 9540
Cycle 1 Day 260400 ± 17200—
Cycle 1 Day 21259000 ± 67300—
SecondaryPhase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose of Enzalutamide

For Phase 2, PK blood samples for assessment of enzalutamide AUC0-24 were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.

Time frame:
Up to 24 hours post-dose on Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and up to 24 hours post-dose on Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Reported as:
Mean · hour*ng/mL
Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose of Enzalutamide
hour*ng/mLPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Cycle 1 Day 1—31400 ± 8430
Cycle 1 Day 260000 ± 17000—
Cycle 1 Day 21253000 ± 64500—
SecondaryPhase 2: Change From Baseline in Functional Assessment of Cancer Therapy-Prostrate (FACT-P): Functional Well-being Subscale (FWB) and Prostate Cancer Subscale (PCS) Scores

FACT-P questionnaire included subscales:physical well-being(PWB) (Questions \[Q\] GP1 to GP7),social/family well-being subscale(SWB) (Q GS1 to GS7),emotional well-being subscale(EWB) (Q GE1 to GE6),functional well-being subscale(FWB) (Q GF1 to GF7) and prostate cancer subscale(PCS) (Q C2, C6, P1 to P8, BL2 and BL5). Each question had 5 responses, 0: "not at all", 1: "a little bit", 2: "somewhat", 3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Q that were reversed (via subtraction of the response from 4) were: GP1-7, GE1, GE3-6, C2, P1-3, P6-P8 and BL2. Total FACT-P score was sum of scores of all sub-scales (PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. Baseline: last value recorded for a variable prior to or on date of randomization. Change from baseline in FWB and PCS scores is presented.

Time frame:
Baseline (Day 1), Cycle (C) 3 Day 57, C 5 Day 113, C 7 Day 169, C 10 Day 253, C 13 Day 337, C 14 Day 421, C 15 Day 505, C 16 Day 589, C 17 Day 673, C 18 Day 757, C 19 Day 841, C 20 Day 925, C 21 Day 1009, C 22 Day 1093, C 23 Day 1177 and C 24 Day 1261
Reported as:
Mean · score on a scale
Phase 2: Change From Baseline in Functional Assessment of Cancer Therapy-Prostrate (FACT-P): Functional Well-being Subscale (FWB) and Prostate Cancer Subscale (PCS) Scores
score on a scalePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
FWB: Cycle 3 Day 57-0.8 ± 4.73-1.2 ± 6.22
FWB: Cycle 5 Day 113-0.8 ± 4.61-0.6 ± 4.14
FWB: Cycle 7 Day 169-0.1 ± 5.681.4 ± 5.72
FWB: Cycle 10 Day 253-0.6 ± 4.82-0.6 ± 5.11
FWB: Cycle 13 Day 3370.4 ± 3.581.1 ± 4.61
FWB: Cycle 14 Day 4212.1 ± 4.321.0 ± 6.44
FWB: Cycle 15 Day 5050.3 ± 2.701.7 ± 5.09
FWB: Cycle 16 Day 5890.4 ± 3.465.0 ± 6.06
FWB: Cycle 17 Day 6731.4 ± 3.502.0 ± 4.64
FWB: Cycle 18 Day 7571.7 ± 1.515.0 ± 4.36
FWB: Cycle 19 Day 8412.6 ± 3.517.5 ± 3.54
FWB: Cycle 20 Day 9252.0 ± 4.004.0 ± 4.24
FWB: Cycle 21 Day 10091.7 ± 2.31—
FWB: Cycle 22 Day 10932.7 ± 4.73—
FWB: Cycle 23 Day 11774.5 ± 6.36—
FWB: Cycle 24 Day 12617.0—
PCS: Cycle 3 Day 57-0.8 ± 5.69-1.3 ± 5.85
PCS: Cycle 5 Day 113-0.9 ± 5.12-0.7 ± 4.60
PCS: Cycle 7 Day 169-1.2 ± 6.07-0.8 ± 5.08
PCS: Cycle 10 Day 2530.0 ± 7.62-0.4 ± 7.89
PCS: Cycle 13 Day 3370.8 ± 5.63-1.8 ± 7.73
PCS: Cycle 14 Day 4210.8 ± 6.82-0.8 ± 5.19
PCS: Cycle 15 Day 5052.0 ± 5.024.1 ± 2.65
PCS: Cycle 16 Day 5892.3 ± 3.492.6 ± 6.26
PCS: Cycle 17 Day 6731.6 ± 5.503.6 ± 3.07
PCS: Cycle 18 Day 7571.3 ± 3.720.2 ± 6.81
PCS: Cycle 19 Day 8411.8 ± 3.507.3 ± 1.80
PCS: Cycle 20 Day 9253.3 ± 4.73-1.0 ± 7.07
PCS: Cycle 21 Day 10095.0 ± 1.73—
PCS: Cycle 22 Day 10936.0 ± 2.65—
PCS: Cycle 23 Day 11776.5 ± 0.71—
PCS: Cycle 24 Day 12613.0—
SecondaryPhase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score

TTD was defined as the interval from date of randomization until date of first clinically meaningful deterioration (3 points or more decline for subscale score, 10 points or more decline for total score) that was confirmed at subsequent visit at least 3 weeks apart with no improvement in between visits or death (by any cause) in absence of a clinically meaningful deterioration, regardless of whether participant discontinued study drug(s) prior to deterioration. PCS included Q C2, C6, P1 to P8, BL2 and BL5. Each question had 5 responses,0: "not at all",1: "a little bit",2: "somewhat",3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Total FACT-P: sum of scores of all sub-scales(PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. TDD in prostate symptoms as assessed by FACT-P: PCS score is presented.

Time frame:
Baseline (Day 1) up to Cycle 24 Day 1261
Reported as:
Median · months
Phase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score
monthsPhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Phase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score11.2 (3.9 to NA)3.7 (2.5 to 11.1)

Adverse events

Collected over TEAEs were collected from first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) to the end of follow-up for death for each participant, up to approximately 259 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Tazemetostat 400 mg + Enzalutamide2/2 (100%)0/2 (0%)2/2 (100%)
Phase 1b: Tazemetostat 600 mg + Enzalutamide2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Phase 1b: Tazemetostat 800 mg + Enzalutamide2/3 (66.7%)0/3 (0%)3/3 (100%)
Phase 1b: Tazemetostat 1200 mg + Enzalutamide3/3 (100%)0/3 (0%)3/3 (100%)
Phase 1b: Tazemetostat 1600 mg + Enzalutamide0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone1/1 (100%)0/1 (0%)1/1 (100%)
Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone3/3 (100%)1/3 (33.3%)3/3 (100%)
Phase 2: Tazemetostat 1200 mg + Enzalutamide7/41 (17.1%)13/41 (31.7%)41/41 (100%)
Phase 2: Enzalutamide18/40 (45%)10/40 (25%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
ArthralgiaMusculoskeletal and connective tissue disorders0/20/30/30/31/30/10/30/31/412/40
PneumoniaInfections and infestations0/20/30/30/30/30/11/30/31/411/40
Urinary tract infectionInfections and infestations0/21/30/30/30/30/10/30/30/411/40
ConstipationGastrointestinal disorders0/20/30/30/31/30/10/30/30/410/40
Type 2 diabetes mellitusMetabolism and nutrition disorders0/20/30/30/30/30/10/31/30/410/40
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/20/30/30/31/30/10/30/30/410/40
HydronephrosisRenal and urinary disorders0/21/30/30/30/30/10/30/30/410/40
Back painMusculoskeletal and connective tissue disorders0/20/30/30/30/30/10/30/30/412/40
Bone painMusculoskeletal and connective tissue disorders0/20/30/30/30/30/10/30/30/411/40
Spinal cord compressionNervous system disorders0/20/30/30/30/30/10/30/31/411/40
Most frequent other events
Showing 10 of 111
Most frequent other events
EventPhase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: Enzalutamide
Back painMusculoskeletal and connective tissue disorders0/22/30/30/31/31/10/31/33/418/40
FatigueGeneral disorders0/23/31/32/31/31/12/30/326/4112/40
ConstipationGastrointestinal disorders0/21/31/31/30/31/11/30/37/416/40
DiarrhoeaGastrointestinal disorders0/20/30/32/32/31/10/30/315/418/40
DiverticulumGastrointestinal disorders0/20/30/30/30/31/10/30/30/410/40
DizzinessNervous system disorders0/20/30/30/30/31/11/30/36/413/40
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders0/20/30/30/30/31/10/31/30/410/40
Productive coughRespiratory, thoracic and mediastinal disorders0/21/30/30/30/31/10/30/30/410/40
TachypnoeaRespiratory, thoracic and mediastinal disorders0/20/30/30/30/31/10/31/30/410/40
Urinary tract infection fungalInfections and infestations0/20/30/30/30/31/10/30/30/410/40

Baseline characteristics

Phase 1b: The safety population included all participants who received any dose of the study drugs. Phase 2: The intent-to-treat (ITT) population included all participants who were randomized into the study.

Age, Customized
Age, Customized(Participants)Phase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: EnzalutamideTotal
<65 years01202010121129
>=65 years22131123292973
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: EnzalutamideTotal
Female00000000000
Male233331334140102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: EnzalutamideTotal
Hispanic or Latino010011015312
Not Hispanic or Latino22322032353384
Unknown or Not Reported00010000146
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: Tazemetostat 400 mg + EnzalutamidePhase 1b: Tazemetostat 600 mg + EnzalutamidePhase 1b: Tazemetostat 800 mg + EnzalutamidePhase 1b: Tazemetostat 1200 mg + EnzalutamidePhase 1b: Tazemetostat 1600 mg + EnzalutamidePhase 1b: Tazemetostat 400 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 600 mg + Abiraterone/PrednisonePhase 1b: Tazemetostat 800 mg + Abiraterone/PrednisonePhase 2: Tazemetostat 1200 mg + EnzalutamidePhase 2: EnzalutamideTotal
American Indian or Alaska Native00000000000
Asian00000000000
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00100000067
White23233133353186
More than one race00000000000
Unknown or Not Reported00000000639
08

Study locations

24 sites
  • Genesis Healthcare Partners
    San Diego, California 92123, United States
  • The Urology Center Of Colorado
    Denver, Colorado 80211, United States
  • Hematology Oncology Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • XCancer - Northwest Oncology and Hematology
    Rolling Meadows, Illinois 60008, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Comprehensive Cancer Centers of Nevada - Central Valley
    Las Vegas, Nevada 89169, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Associated Medical Professionals of NY, PLLC - Urology
    Syracuse, New York 13210, United States
  • Montefiore Einstein Center for Cancer Care
    The Bronx, New York 10461, United States
  • University of Pittsburgh Medical Center - Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • SCRI - Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Urology Associates P.C.
    Hendersonville, Tennessee 37075, United States
  • XCancer - Tennesee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • SCRI - Tennessee Oncology Nashville
    Nashville, Tennessee 37203, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • Academisch Ziekenhuis Groeninge Campus Kennedylaan
    Kortrijk, West Vlaanderen, Belgium
  • Hospital Universitario de Jerez de la Frontera
    Jerez de la Frontera, Cadiz, Spain
  • Hospital de la Santa Creu i. Sant Pau
    Barcelona, Spain
  • Hospital del Mar Parc de Salut Mar
    Barcelona, Spain
  • Hospital Clinico San Carlos
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Nov 2024, 59 months.

Results were first posted in Mar 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 27, 2019
StartActual
Nov 18, 2019
Primary completionActual
Nov 4, 2024
CompletionActual
Nov 4, 2024
Results first posted
Mar 10, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04179864
Lead sponsor
Epizyme, Inc.
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Nov 18, 2019
Primary completion
Nov 4, 2024
Completion
Nov 4, 2024
Results posted
Mar 10, 2026
Last update
Mar 10, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tazemetostat · Enzalutamide

Start the discussion